No Data
Scotiabank Initiates Coverage On Zai Lab With Sector Outperform Rating, Announces Price Target of $55
National People's Congress representative, Zhao Jing of Shandong Buchang Pharmaceuticals: "The 'AI+' is reaching a critical point of explosion. It is recommended to utilize AI to empower the inheritance and innovation of Traditional Chinese Medicine | Two
① Zhao Jing, a representative of the National People's Congress and Vice Director of Shandong Buchang Pharmaceuticals, brought the proposal "Utilizing AI to Empower the Inheritance and Innovation of Traditional Chinese Medicine and Build a New Pattern of Development for Traditional Chinese Medicine with 'Asia Vets + Technology'" to this year's Two Sessions, aiming to promote the intelligent upgrade of the Traditional Chinese Medicine industry through AI technology. ② Zhao Jing stated that the development of large models like DeepSeek has indeed pushed the integration of Traditional Chinese Medicine and AI to a critical point of explosion.
China's Policy Reforms Gain Momentum
BeiGene Shares Are Trading Higher After the Company Announced FDA Approval of Tevimbra/chemotherapy Combination.
B of A Securities Downgrades Zai Lab to Neutral, Raises Price Target to $36.1
Zai Lab Analyst Ratings